Verzenio

VERZENIO® is a kinase inhibitor.

Available in Tablets: 50 mg, 100 mg, 150 mg, and 200 mg provided as immediate-release oval white, beige, or yellow tablets indicated to be taken with or without food twice daily with a recommended and approved starting dose of 150mg for combination therapy or 200mg for monotherapy.

Early Breast Cancer

VERZENIO® (abemaciclib) is indicated:

• in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of recurrence [see Clinical Studies ].

Advanced or Metastatic Breast Cancer

VERZENIO (abemaciclib) is indicated:

• in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.
• in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.
• as monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.